August 9, 2019
Takeda Pharmaceutical said on August 8 that it has filed a subcutaneous formulation of its inflammatory bowel disease treatment Entyvio (vedolizumab) in Japan as a maintenance therapy in adults with moderately to severely active ulcerative colitis (UC). Entyvio is currently...read more